Company Encyclopedia
View More
name
TIANYUAN HEALTH
00557.HK
China Tian Yuan Healthcare Group Limited, an investment holding company, provides healthcare related services in Hong Kong, the People’s Republic of China, and Korea. It operates through Investment Holding, Healthcare, Money Lending and Related Business, and Hospitality segments. The company offers procurement, marketing, and management services to the healthcare industry; and plastic surgery and medical beauty services, licenses trademarks, as well as optimal functionality for the properties; custom solutions, such as custom booking engines, website design and development, cutting-edge applications, and independent hotel management services. It also invests in equity investments; offers loans and related services; refers and introduces of lenders and borrowers; and provides procurement services to the hospitality industry.
616.49 B
00557.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Hotels, Resorts and Cruise LinesIndustry
Industry Ranking30/43
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.15%E
    • Profit Margin-155.23%E
    • Gross Margin96.41%A
  • Growth ScoreE
    • Revenue YoY-43.78%E
    • Net Profit YoY-118.30%E
    • Total Assets YoY-9.49%E
    • Net Assets YoY-16.58%E
  • Cash ScoreE
    • Cash Flow Margin-64.42%D
    • OCF YoY-43.78%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreB
    • Gearing Ratio34.44%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    "Performance" TIANYUAN HEALTH's mid-term loss narrowed to 3.065 million yuan

    TIANYUAN HEALTH announced its interim results for the six months ended June, recording a revenue of HKD 8.44 million, a year-on-year decrease of 43.2%. The loss narrowed from HKD 5.61 million in the same period last year to HKD 3.065 million, with a loss per share of 0.77 cents. No dividend was declared

    AASTOCKS·
    HK
    00557
    -1.28%
    AASTOCKS·
    HK
    00557
    -1.28%

    TIANYUAN HEALTH released its interim results, with a loss attributable to shareholders of HKD 3.065 million, a year-on-year decrease of 45.33%

    TIANYUAN HEALTH released its interim results for the period ending June 30, 2025, with a revenue of HKD 8.436 million, a year-on-year decrease of 43.23%. The loss attributable to shareholders was HKD 3.065 million, a year-on-year decrease of 45.33%, with a loss per share of HKD 0.0077. The reduction in loss was mainly due to a decrease in valuation losses from securities trading during the period, a reversal of expected credit losses, and foreign exchange gains turning positive, offsetting the decline in total revenue

    Zhitong·
    HK
    00557
    -1.28%
    Zhitong·
    HK
    00557
    -1.28%

    "Profit Warning" TIANYUAN HEALTH revenue decreases, expects to continue seeing losses in mid-term results

    TIANYUAN HEALTH issued a profit warning, expecting a net loss of approximately HKD 8.4 million for the six months ending in June, compared to a loss of HKD 9 million in the same period last year. The anticipated loss is mainly due to an estimated total revenue decrease of about 44% to HKD 8.4 million

    AASTOCKS·
    HK
    00557
    -1.28%
    AASTOCKS·
    HK
    00557
    -1.28%

    TIANYUAN HEALTH issues profit warning, expects to incur a net loss of approximately HKD 8.4 million in the first half of the year

    TIANYUAN HEALTH expects to record a net loss of approximately HKD 8.4 million in the first half of 2025, an improvement compared to the previous period's loss of HKD 9 million. Total revenue is expected to be around HKD 8.4 million, a year-on-year decrease of approximately 44%. The main reason is the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Aesthetic Hospital, resulting in a decrease in medical business revenue of no less than HKD 6.2 million. The board believes that the net loss is primarily due to the decrease in total revenue

    Zhitong·
    HK
    00557
    -1.28%
    Zhitong·
    HK
    00557
    -1.28%

    TIANYUAN HEALTH: Hengqin Hanyue Mei and Shanghai Rifu plan to increase capital in Shanghai Rifu

    TIANYUAN HEALTH announced that Hengqin Hanyue Mei and Shanghai Rifu will increase their capital contribution to Shanghai Rifu, totaling RMB 25.5152 million (approximately HKD 27.6116 million). The capital increase will be conducted through the conversion of debt and cash contributions, and after the increase, Shanghai Rifu's registered capital will rise to RMB 27.8998 million. This capital increase aims to meet the working capital needs of Shanghai Rifu, enhance its development capabilities, and improve the group's competitiveness in the Chinese healthcare service market

    Zhitong·
    HK
    00557
    -1.28%
    Zhitong·
    HK
    00557
    -1.28%
    © 2025 Longbridge｜Disclaimer